Earnings Highlights
Thermo Fisher Scientific Inc. reported its second‑quarter 2026 results for the period ended June 27, 2026. Adjusted earnings per share were $6.03, surpassing the analyst consensus estimate of $5.72 by $0.31.
Financial Metrics
Revenue increased 10% year‑over‑year to $11.99 billion, beating the consensus forecast of $11.71 billion and rising from $10.85 billion in the comparable quarter of the prior year. Organic revenue growth was 5%. GAAP diluted earnings per share grew 9% to $4.68. Adjusted operating margin expanded to 22.8%, up from 21.9% in the prior‑year quarter.
Segment Performance
The Laboratory Products and Biopharma Services segment generated $6.69 billion in revenue, representing 55.8% of total sales.
Operational Updates
During the quarter the company launched next‑generation Orbitrap platforms featuring AI‑driven analytics and opened a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. It also announced the divestiture of its microbiology business.
Shareholder Actions
Thermo Fisher repurchased $1.0 billion of its own stock in the quarter.
Market Reaction and Outlook
Following the earnings release, Thermo Fisher’s shares rose 3.14% in pre‑market trading. The company indicated that it will provide updated 2026 financial guidance during its earnings conference call.